Tesi Raymond Joseph - Apr 19, 2024 Form 4/A Insider Report for Inmune Bio, Inc. (INMB)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Raymond Joseph Tesi
Stock symbol
INMB
Transactions as of
Apr 19, 2024
Transactions value $
$152,246
Form type
4/A
Date filed
4/24/2024, 02:08 PM
Date Of Original Report
Apr 23, 2024
Previous filing
Feb 21, 2023
Next filing
May 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INMB Common Stock Purchase $150K +18K +1.19% $8.32 1.54M Apr 19, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INMB Common Stock Warrants (right to buy) Purchase $2.25K +18K $0.13* 18K Apr 19, 2024 Common Stock 18K $9.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.

Remarks:

The original Form 4, filed on April 23, 2024 is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the transaction as an award in column 3 of Table I and column 4 of table II instead of a purchase. The reporting person purchased the securities in a registered direct transaction from the Company.